Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses to Contact the Firm

RHHBY, ITCI

IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Roche Holding AG and Encourages Investors with Losses to Contact the Firm

Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Roche Holding AG (“Roche Holding” or the “Company”) (Other OTC: RHHBY) for possible violations of federal securities laws between March 2, 2017 and June 5, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the August 7, 2017 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here .

You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or failed to disclose that the combination of the Company’s breast cancer drug, Perjeta, and its older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer; and that as a result, Roche Holding’s statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When this information was released to the public, shares of Roche Holding fell in value, causing investors harm according to the Complaint.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/